Andrx Announces Final Approval of Famotidine 20 & 40 MG Tablets.

Business Editors/Health & Medical Writers

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--April 17, 2001

Andrx Corporation - Andrx Group (Nasdaq:ADRX) announced today that the U.S. Food and Drug Administration has awarded final approval for Famotidine 20-mg and 40-mg tablets to Carlsbad Technologies Inc. (CTI), which is Andrx' joint venture partner in CARAN. Andrx has already commenced shipment of this product. CTI is responsible for the development and manufacture of the CARAN joint venture products, including Famotidine, and Andrx is responsible for their distribution.

Famotidine is the generic equivalent to Merck's drug Pepcid(R) for the treatment of ulcers, gastroesophageal reflux disease and pathological hypersecretory conditions. The combined U.S. annual brand sales of the 20-mg and 40-mg strengths were approximately $585 million in 2000.

Forward-looking statements (statements which are not historical facts) in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained in this report that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "to," "expect," "believe," "anticipate," "intend," "could," "would," "estimate," or "continue" or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements. Investors are cautioned that all forward-looking statements involve risk and uncertainties. Andrx Group is a class of common stock of Andrx Corporation, therefore, Andrx Corporation shareholders are subject to the risks and uncertainties described in Andrx Corporation's filings with the Securities and Exchange Commission, including Andrx Corporation's Annual Report on Form 10-K for the year ended December 31, 2000.